endocervix and endometrium in patients with endometrial cancer. Due to the ease of obtaining the material from the cervix during cytological screening, the expression of selected proteins might be used as a predictive factor in endometrial cancer.

**Methodology**
The study was performed on group of 101 patients with type I and II endometrial carcinoma using immunohistochemical methods.

**Results**
Our results showed that both cadherins were expressed in the endocervix. In endometrial cancer type I, no significant differences were found in the expression of cadherins between the tumor and the cervix. It is possible to suspect an evenly ongoing neoplastic process both in the primary site and in the cervix. Statistically significant differences in the results turned out to be in the case of type II endometrial cancer, where a higher cadherin expression was noted in the tumor mass compared to the cervix, which suggests a greater dynamic of the EMT process in the tumor itself than in the cervix.

**Conclusion**
Our results may have significant clinical outcomes in the diagnosis of endometrial cancer.

**2022-RA-1106-ESGO**
**LAPAROSCOPIC VERSUS OPEN ABDOMINAL HYSTEROCTOMY IN ENDOMETRIAL CANCER PATIENTS: ANALYSIS OF OUTCOME ACCORDING TO RISK GROUP**
Valentina Auletta, Davit Bokhua, Angela Kather, Ingo B Runnebaum. Gynaecology and Reproductive Medicine, Jena University Hospital, Jena, Germany

10.1136/ijgc-2022-ESGO.290

**Introduction/Background**
For treatment of low-risk endometrial cancer, laparoscopic hysterectomy is the standard surgery approach. On the other hand, oncologic safety of minimally invasive technique in high risk disease has not yet been proven.

**Methodology**
Between 1996 and 2010, 359 endometrial cancer patients underwent laparoscopic or abdominal hysterectomy at Jena University Hospital. Recurrence rate and survival were analysed depending on surgical approach and risk categorization by classical histopathology (low-risk: stage IA without nodes metastasis, G2 or G2 with endometroid carcinoma; high-risk: stage IB or G3 or with nodes metastasis; G2 or G2 with endometroid carcinoma; high-risk: stage IB or G3 or with nodes metastasis or serous papillary or clear cell type). Median follow-up was 72 months (minimum=2, maximum=214).

**Results**
In low risk patients, disease-free survival (DFS) rate was 95.6% and overall survival (OS) rate was 96.6% after laparoscopic hysterectomy (n=158) compared to DFS rate of 92.9% and OS rate of 100% after abdominal hysterectomy (n=43). In high risk patients, we found a DFS rate of 75.3% and OS rate of 85.1% in the laparoscopy group (n=97), while DFS rate was 73.3% and OS rate was 84.2% in the open surgery group (n=61). Proportional hazards assumption of Kaplan-Meier curves was not satisfied.

**Conclusion**
Long-term oncologic outcome of the laparoscopic procedure was not inferior compared to open abdominal hysterectomy in both low risk and high risk endometrial carcinoma patients according to data from our cohort. Results from patients treated in our center between 2011 and 2021 are under progress.

**2022-RA-1124-ESGO**
**PREDICTORS OF INVASIVE CARCINOMA IN ENDOMETRIAL HYPERPLASIA AND ITS INFLUENCE ON SURGICAL MANAGEMENT**
1Carmen De la Fuente Méndez, 2María Alonso-Espias, 3Virginia García-Pineda, 2Myriam Gracia, 1Jaime Siegrist, 2María Dolores Dietero, 4Alicia Hernández, 2Ignacio Zapardiel. La Paz University Hospital, Madrid, Spain; 2Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain

10.1136/ijgc-2022-ESGO.291

**Introduction/Background**
Endometrial hyperplasia consists of the proliferation of endometrial glands due to chronic exposure to high estrogen levels without the compensatory stimulus of progesterone. Other related factors are age, menopause and obesity. Transformation to endometrial cancer is greater if the hyperplasia is atypical; however, no reliable predictors have yet been described. The aim of this study is to analyze factors that can predict the evolution of hyperplasia to endometrial carcinoma.

**Methodology**
A retrospective study was performed on patients diagnosed with endometrial hyperplasia at Hospital La Paz from January 2016 to December 2021. Factors that could influence the development of endometrial cancer were analyzed, as well as those that could influence oncologic outcomes.

**Results**
169 patients with endometrial hyperplasia were included, of which 41 progressed to carcinoma. In this group, 92.7% of the carcinomas were endometrioid, 82.9% were diagnosed at FIGO stage IA, 68.3% were G1; statistical significance was observed in these associations. 3.6% of patients suffered recurrences, in which endometrioid carcinoma, stages IA, IB and IV, G2 and G3 and combined treatment showed significant association with this event. Of the disease-free patients, 96.8% had endometrioid carcinoma and 87.1% had stage IA. No significant differences were detected in survival studies.

**Conclusion**
Advanced age, menopause, atypical hyperplasia, family history of cancer (specifically breast, colon and endometrial) and surgical treatment are statistically significantly associated with greater progression to endometrial cancer.

**2022-RA-1128-ESGO**
**HAS ENDOMETRIAL CANCER TREATMENT CHANGED DURING THE LAST YEARS? A CANCER REGISTRY DATA-BASED APPROACH TO MONITOR EXPECTED TREATMENT CHANGES AFTER THE RELEASE OF THE CORRESPONDING S3 GUIDELINE**
1Annemarie Schultz, 2Niklas Jobst, 2Gerhard Gebauer. 1Annemarie Schultz, 2Niklas Jobst, 2Gerhard Gebauer. 1Annemarie Schultz, 2Niklas Jobst, 2Gerhard Gebauer.

1Gynecology and Obstetrics, Asklepios Klinik Barmbek, Hamburg, Germany; 2Gynecology and Obstetrics, Asklepios Klinik Barmbek, Hamburg, Germany

10.1136/ijgc-2022-ESGO.292

**Introduction/Background**
With approximately 11,000 new cases annually, endometrial cancer is the fourth most malignant in women in Germany. In April 2018 the S3 endometrial cancer guideline was released as part of the Germany oncology guideline program to promote quality and transparency of medical care. The S3 guideline advised on various aspects of endometrial cancer treatment such as surgical strategies and adjuvant therapy. Recommendations of this S3